The Uremic Toxin Indoxyl Sulphate Enhances Macrophage Response to LPS

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Adesso, Simona ^a   Popolo, Ada ^a   Bianco, Giuseppe ^a   Sorrentino, Rosalinda ^a   Pinto, Aldo ^a   Autore, Giuseppina ^a   Marzocco, Stefania ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CYCLOOXYGENASE 2; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOXYL SULPHATE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREMIC TOXIN;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD LEVEL; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOFLUORESCENCE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; UREMIA;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CALCIUM; CELL PROLIFERATION; CYTOKINES; ESCHERICHIA COLI; FEMALE; HOMEOSTASIS; INDICAN; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84884751824     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076778     Document Type: Article

References (62)

1. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, et al. (2001) Uremic toxicity: Present state of the art. Int J Artif Organs 24: 695-725.
2. Raff AC, Meyer TW, Hostetter TH, (2008) New insights into uremic toxicity. Curr Opin Nephrol Hypertens 17: 560-565.
3. Di Micco L, Marzocco S, Sirico ML, Torraca S, Di Iorio B, (2012) Does daily dialysis improve hypertension in chronic haemodialysis patients? Current Hypertension Reviews 8(4): 291-295.
4. Niwa T, Takeda N, Tatematsu A, Maeda K, (1988) Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 34: 2264-2267.
5. Niwa T (2001) Uremic Toxicity, Indoxyl sulfate. In: Massry SG, Glassock RJ (eds). Textbook of Nephrology. Philadelphia, PA: LippincottWilliams & Wilkins, 1269-1272.
6. Niwa T, (1996) Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 16: 167-182.
7. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, et al. (2008) All-cause mortality attributable to chronic kidney disease: A prospective cohort study based on 462 293 adults in Taiwan. Lancet 371: 2173-2182.
8. Drey N, Roderick P, Mullee M, Rogerson M, (2003) A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 42: 677-684.
9. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, et al. (2008) Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3: 1526-1533.
10. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, et al. (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17: 2034-2047.
11. Hauser AB, Stinghen AE, Kato S, Bucharles S, Aita C, et al. (2006) Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int 28(3): 183-187.
12. Libetta C, Sepe V, Esposito P, Galli F, Dal Canton A, (2011) Oxidative stress and inflammation: Implications in uremia and hemodialysis. Clin Biochem 44: 1189-1198.
13. Popolo A, Autore G, Pinto A, Marzocco S, (2013) Oxidative stress in cardiovascular and renal disease. Free Radic Res 47(5): 346-356.
14. Morena M, Cristol JP, Senecal L, Leray-Moragues H, Krieter D, et al. (2002) Oxidative stress in hemodialysis patients: is NADPH oxidase complex the culprit? Kidney Int 61: 109-114.
15. Rodriguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heimburger O, et al. (2005) Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. Atherosclerosis 180: 333-340.
16. Cohen G, Hörl W, (2012) Immune Dysfunction in Uremia-An Update. Toxins 4: 962-990.
17. Autore G, Marzocco S, Sorrentino R, Mirone V, Baydoun A, et al. (1999) In vitro and in vivo TNFα synthesis by methylguanidine, an uremic catabolyte. Life Sciences 65(11): 121-127.
18. Marzocco S, Di Paola R, Serraino I, Sorrentino R, Meli R, et al. (2004) Effect of methylguanidine in carrageenan-induced acute inflammation in the rats. Eur J Pharmacol 484(2-3): 341-350.
19. Marzocco S, Di Paola R, Genovese T, Sorrentino R, Britti D, et al. (2004) Methylguanidine reduces the development of non septic shock induced by zymosan in mice. Life Sci 75(12): 1417-1433.
20. Marzocco S, Di Paola R, Ribecco MT, Sorrentino R, Domenico B, et al. (2004) Effect of methylguanidine in a model of septic shock induced by LPS. Free Radical Res 38(11): 1143-1153.
21. Ito S, Osaka M, Higuchi Y, Nishijima F, Ishii H, et al. (2010) Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin. J Biol Chem 285: 38869-38875.
22. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, et al. (2003) Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63(5): 1934-1943.
23. Cioffi G, Dal Piaz F, De Caprariis P, Sanogo R, Marzocco S, et al. (2006) Antiproliferative triterpene saponins from Entada africana. J Nat Prod 69(9): 1323-1329.
24. Ben Jemia M, Kchouk ME, Senatore F, Autore G, Marzocco S, et al. (2013) Antiproliferative activity of hexane extract from Tunisian Cistus libanotis, Cistus monspeliensis and Cistus villosus. Chem Cent J 5,7(1):47. Available: http://www.journal.chemistrycentral.com/content/7/1/47. Accessed 5 March 2013.
25. Autore G, Caruso A, Marzocco S, Nicolaus B, Palladino C, et al. (2010) Acetamide derivatives with antioxidant activity and potential anti-inflammatory activity. Molecules 15(3): 2028-2038.
26. Bianco G, Russo R, Marzocco S, Velotto S, Autore G, et al. (2012) Modulation of macrophage activity by aflatoxins B1 and B2 and their metabolites aflatoxins M1 and M2. Toxicon 59(6): 644-650.
27. Bianco G, Fontanella B, Severino L, Quaroni A, Autore G, et al. (2012) Nivalenol and deoxynivalenol affect rat intestinal epithelial cells: a concentration related study. PLoS One7: 12. Available: http://http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052051. Accessed 14 December 2012.
28. Marzocco S, Popolo A, Bianco G, Pinto A, Autore G, (2010) Pro-apoptotic effect of methylguanidine on hydrogen peroxide-treated rat glioma cell line. Neurochem Int 57(5): 518-524.
29. Tak P, Firestein GS, (2001) NF-κB: a key role in inflammatory diseases. J Clin Invest 7(1): 7-11.
30. Stenvinkel P, Pecoits-Filho R, Lindholm B, (2003) Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 14: 1927-1939.
31. Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, et al. (2007) Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. Nephrol Dial Transplant 22: 3381-3390.
32. Zafarullah M, Li WQ, Sylvester J, Ahmad M, (2003) Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60: 6-20.
33. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, et al. (2007) The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 5(6): 1302-1308.
34. Yu M, Kim YJ, Kang DH, (2011) Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 6(1): 30-39.
35. Mozar A, Louvet L, Morlière P, Godin C, Boudot C, et al. (2011) Uremic toxin indoxyl sulfate inhibits human vascular smooth muscle cell proliferation. Ther Apher Dial 15(2): 135-139.
36. Shimizu H, Yisireyili M, Higashiyama Y, Nishijima F, Niwa T, (2013) Indoxyl sulfate upregulates renal expression of ICAM-1 via production of ROS and activation of NF-κB and p53 in proximal tubular cells. Life Sci 92(2): 143-148.
37. Fortuno A, Beloqui O, San Jose G, Moreno MU, Zalba G, et al. (2005) Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidasedependent superoxide production in patients with early chronic kidney disease. Kidney Int Suppl 99:71-75.
38. Castilla P, Davalos A, Teruel JL, Cerrato F, Fernandez-Lucs M, et al. (2008) Comparative effects of dietary supplementation with red grape juice and vitamin E on producing of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. Am J Clin Nutr 87: 1053-1061.
39. Kárpáti I, Seres I, Mátyus J, Ben T, Paragh G, et al. (2001) Which parameters affect cytosolic free calcium in polymorphonuclear leukocytes of haemodialysis patients? Nephrol Dial Transplant 16(7): 1409-1415.
40. Raddassi K, Berthon B, Petit JF, Lemaire G, (1994) Role of calcium in the activation of mouse peritoneal macrophages: induction of NO synthase by calcium ionophores and thapsigargin. Cell Immunol 153(2): 443-455.
41. Berridge MJ, Bootman MD, Lipp P, (1998) Calcium-a life and death signal. Nature 395: 645-648.
42. Sarnak MJ, Jaber BL, (2000) Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 58: 1758-1764.
43. Parrillo JE, (1993) Pathogenetic mechanisms of septic shock,.N Engl J Med. 328(20): 1471-1477.
44. Holmes CL, Walley KR, (2003) The evaluation and management of shock. Clin Chest Med 24(4): 775-789.
45. Brown DM, Donaldson K, Borm PJ, Schins RP, Dehnhardt M, et al. (2004) Calcium and ROS-mediated activation of transcription factors and TNF-alpha cytokine gene expression in macrophages exposed to ultrafine particles. Am J Physiol Lung Cell Mol Physiol 286(2): 344-353.
46. Masai N, Tatebe J, Yoshino G, Morita T, (2010) Indoxyl sulfate stimulates monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells by inducing oxidative stress through activation of the NADPH oxidase-nuclear factor-κB pathway. Circ J 74(10): 2216-2224.
47. Dugo L, Marzocco S, Mazzon E, Di Paola R, Genovese T, et al. (2004) Effects of GW274150, a novel and selective inhibitor of iNOS activity, in acute lung inflammation. Br J Pharmacol 141(6): 979-987.
48. Thiemermann C, (1994) The role of the L-arginine: nitric oxide pathway in circulatory shock. Adv Pharmacol 28: 45-79.
49. Szabò C, (1995) Alterations in nitric oxide production in various forms of circulatory shock. N Horiz 3(1): 2-32.
50. Thiemermann C, (1997) Nitric oxide and septic shock. Gen Pharmacol 29(2): 159-166.
51. Ahmad N, Chen LC, Gordon MA, Laskin JD, Laskin DL, (2002) Regulation of cyclooxygenase-2 by nitric oxide in activatedhepatic macrophages during acute endotoxemia J Leuk Biol. 71(6): 1005-1011.
52. Thiemermann C, Wu CC, Szabò C, Perretti M, Vane JR, (1993) Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. Br J Pharmacol 110(1): 177-182.
53. Hischi S, Hayaschi I, Hayaschi M, Yamaki K, Utsunomiya I, (1989) Pharmacological demonstration of inflammatory mediators using experimental inflammatory models: rat pleuresy induced by carrageenan and phorbol myristate acetate. Dermatologica 179: 68-71.
54. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, et al. (1998) Immunologic function and survival in hemodialysis patients. Kidney Int 54, 236- 244.
55. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, et al. (2005) IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 67: 1216- 1233.
56. Kaysen GA, Eiserich JP, (2004) The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 15: 538-548.
57. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, et al. (2008) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65: 1009-1016.
58. Carrero JJ, Stenvinkel P (2009) Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: A hypothesis proposal. Clin J Am Soc Nephrol: 4 (1), 49-55.
59. Marzocco S, Dal Piaz F, Di Micco L, Autore G, Torraca S, et al. (2013) Very low protein diet reduces Indoxyl sulfate levels in Chronic Kidney Disease. Blood Purif 13: 196-201.
60. Patel KP, Luo FJ, Plummer NS, Hostetter TH, Meyer TW, (2012) The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin J Am Soc Nephrol 7(6): 982-988.
61. Niwa T, (2011) Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Ther Apher Dial 15(2): 120-124.
62. Ito S, Higuchi Y, Yagi Y, Nishijima F, Yamato H, et al. (2013) Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol 93(6): 837-845.